Efficacy of schedule-dependent metronomic S-1 chemotherapy in human oral squamous cell carcinoma cells

  • Authors:
    • Tarannum Ferdous
    • Koji Harada
    • Takanori Kin
    • Toyoko Harada
    • Yoshiya Ueyama
  • View Affiliations

  • Published online on: May 20, 2013     https://doi.org/10.3892/ijo.2013.1950
  • Pages: 271-279
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Metronomic chemotherapy is based on administration of anticancer agents at low-doses at close regular intervals with no prolonged breaks, and aims to inhibit vascular endothelial cells as well as tumor cells. Recently, it was suggested that metronomic chemotherapy exerts anti-angiogenic effects by inducing thrombospondin-1 (TSP-1) and early growth response-1 (EGR-1), and antitumor effects by suppressing cancer stem cells. S-1 is a novel orally administered anticancer drug that is a combination of tegafur, 5-chloro-2, 4-dihydroxypyridine and oteracil potassium for maintaining efficacious concentrations of 5-FU and reducing the serious gastrointestinal toxicity associated with 5-FU. In the present study, we tried to determine the suitable administration method of S-1 against oral squamous cell carcinoma as a metronomic chemotherapy. We performed in vivo experiments in which tumor-bearing nude mice were used to examine the antitumor activity of S-1 (6.9 mg/kg). HSC2 tumors were treated with three different regimens, given as 4-week treatment and 2-week rest (4W-2W, 1 cycle); 2-week treatment and 1-week rest (2W-1W, 2 cycles); or alternate days treatment (1D-1D, 6 weeks). A fourth group served as control. Antitumor effects and body weight changes were compared in each group. Expression of TSP-1, EGR-1, CD31 and CD44 in HSC2 tumors was examined by immunohistochemistry. The treated groups showed higher tumor growth inhibition compared to the control group, and the relative tumor growth inhibition was not different between the treated groups. Briefly, each relative tumor growth inhibition was 32.4% (4W-2W), 39.6% (2W-1W) and 37.0% (1D-1D). During treatment periods, body weights were lower in the mice with 4W-2W or 2W-1W than 1D-1D or control. Moreover, reduction of microvessel density and CD44 expression, and induction of TSP-1 and EGR-1 expression was markedly seen in 1D-1D-treated tumors compared to 4W-2W-, 2W-1W-treated tumors or untreated control tumors by immunohistochemistry. These findings suggest that the 1D-1D regimen is more useful than the 4W-2W or 2W-1W regimen as a metronomic chemotherapy.
View Figures
View References

Related Articles

Journal Cover

July 2013
Volume 43 Issue 1

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ferdous T, Harada K, Kin T, Harada T and Ueyama Y: Efficacy of schedule-dependent metronomic S-1 chemotherapy in human oral squamous cell carcinoma cells. Int J Oncol 43: 271-279, 2013
APA
Ferdous, T., Harada, K., Kin, T., Harada, T., & Ueyama, Y. (2013). Efficacy of schedule-dependent metronomic S-1 chemotherapy in human oral squamous cell carcinoma cells. International Journal of Oncology, 43, 271-279. https://doi.org/10.3892/ijo.2013.1950
MLA
Ferdous, T., Harada, K., Kin, T., Harada, T., Ueyama, Y."Efficacy of schedule-dependent metronomic S-1 chemotherapy in human oral squamous cell carcinoma cells". International Journal of Oncology 43.1 (2013): 271-279.
Chicago
Ferdous, T., Harada, K., Kin, T., Harada, T., Ueyama, Y."Efficacy of schedule-dependent metronomic S-1 chemotherapy in human oral squamous cell carcinoma cells". International Journal of Oncology 43, no. 1 (2013): 271-279. https://doi.org/10.3892/ijo.2013.1950